GUMM - Eliminate the Common Cold Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: X-ray Vision who wrote (333)	2/17/1999 10:08:00 PM
From: out_of_the_loop	Read Replies (1) of 5582

It is infinitely cheaper to produce zinc gluconate then to genetically engineer ICAM molecules. MUSC will have to partner with a drug company if they have not yet done so, and there are many other stumbling blocks in the way. It may work and work well, however, and tests will have to be done. But they will be no competition for an otc medication already on the shelves and publicized. There may be situation where they find it works better, but I doubt it (based on the same mechanism of action), although it is worth testing. Actually, it might be interesting to perform affinity studies of the ICAM molecules for the receptor and compare them to zinc gluconate/zinullose. It is also possible that the zinullose matrix will hold the receptor hostage better. One thing is clear from these studies. People believe in and are studying this mechanism of action. It is not some crap fantasy. This is all my opinion and I admit some prejudice as a GUMM investor. Thanks for bringing this to the attention of the thread and please let us know if you have more details.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next